GenomeQuest and Servier Develop Software to Integrate Microarray Data to qPCR Tools
Complete the form below to unlock access to ALL audio articles.
GenomeQuest, Inc. has announced collaboration with Servier to connect results from high-throughput microarray experiments to qPCR platforms from different vendors, including Servier proprietary reagent data sets.
As part of the collaboration, Servier provided key scientific insights and guidance to form product requirements while GenomeQuest, Inc. leveraged its many years of expertise in bioinformatics, high-performance computing, and data management.
The collaboration produced a system that optimizes experimental study design and analysis by providing a simple way to view and analyze the exhaustive set of transcripts and biological assays for a gene.
The deliverables of the collaboration to Servier include highly maintainable gene catalogs for human, mouse, and rat and a companion visualization module that integrates all Servier proprietary content with public and vendor reagent libraries.
In turn, GenomeQuest, Inc. has retained the right to commercialize the software and know-how to help other companies with a similar requirement integrate their own proprietary data sets.
Emmanuel Canet, M.D. Ph.D, Vice President of Research and Development of Servier, said, "We chose to work with GenomeQuest, Inc. because we have a long track record of successful innovations working with Jean-Jacques Codani PhD. and his team on a range of bioinformatics projects over many years.”
“More importantly, we could see that GenomeQuest, Inc. management had a vision for how to commercialize the results of our collaboration. This set the stage for a true win-win partnership. Servier gains early access to the technology and GenomeQuest is able to leverage the investment for the long-term.” Canet added.
Ronald Ranauro, President and CEO of GenomeQuest, Inc., said, "It is GenomeQuest's privilege to work closely with Servier and gain access to their scientific team to leverage their scientific insights into our long-term product strategy."